Preclinical studies have established the ability of T-cells targeting this unique, tumor-specific epitope to proliferate and release cytokines in response to stimulation with the mutant EGFRvIII antigen, but not wild-type EGFR (41). The gene discussed is EGFR; the disease is neoplasm.